Tumor News and Research

RSS

NHS Supply Chain signs deal to purchase 10 Elekta Synergy radiation therapy treatment systems

NHS Supply Chain will bring state-of-the-art cancer treatment to the United Kingdom by signing a deal to purchase ten Elekta Synergy radiation therapy treatment systems.

From Elekta 18 Jun 2012

Surprising effects of brain injury

When Maria Ross' husband found his healthy and active wife unconscious on the bathroom floor, the pair had no idea they would embark on a journey into the world of brain injury, learning more about how trauma affects the brain - and your identity - than they ever cared to know.

16 Jun 2012

New approach to drug design may yield more effective and less toxic cancer medicines

A new approach to drug design, pioneered by a group of researchers at the University of California, San Francisco (UCSF) and Mt. Sinai, New York, promises to help identify future drugs to fight cancer and other diseases that will be more effective and have fewer side effects.

16 Jun 2012

Psoriasis TNF-α therapeutic effects mediated by MSC antioxidant reduction

The therapeutic effects of tumor necrosis factor-α inhibitors in psoriasis occur through a reduction in the antioxidant response of mesenchymal stem cells, suggest study findings.

15 Jun 2012

Anti-TNFs increase risk for herpes zoster infections in IRD patients

Patients with inflammatory rheumatic diseases who are treated with anti-tumor necrosis factor medications are significantly more likely to experience herpes zoster infections than those treated with traditional disease-modifying anti-rheumatic drugs, study results show.

15 Jun 2012

Rheumatism drugs may increase shingles risk

Patients with inflammatory rheumatic disease treated with one of the most effective medicines for their disease face a substantially increased risk for developing shingles, warn European researchers who suggest vaccination may be an option.

15 Jun 2012

Drug shows promise as skin cancer treatment

A new drug for a type of skin cancer caused by a rare genetic disease can not only substantially shrink the tumors, but can also prevent the growth of new cancers, US investigators have discovered.

15 Jun 2012

DFINE completes initial phase of STAR Tumor Ablation System trial

DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, today announced an upcoming poster presentation at the World Congress of Interventional Oncology (WCIO), June 14-18 in Chicago.

15 Jun 2012

Study: Quirky fruit fly gene can help develop new weapons against cancer

Loyola University Chicago researchers are taking advantage of a quirk in the evolution of fruit fly genes to help develop new weapons against cancer.

15 Jun 2012

Variations in microRNA expression within breast tumors can lead to sampling bias

Certain short strands of RNA, known as microRNAs (miRNAs), have been linked to the progression and metastasis of breast cancer and may provide information about prognosis. However, studies of miRNA expression profiles often report conflicting findings. While the potential for using miRNAs in breast cancer diagnosis is promising, scientists report in a new study published online today in The Journal of Molecular Diagnostics that differences in the amount and types of miRNA within breast tumors can be misleading.

15 Jun 2012

Unifying theory on causes of cancer metastases

A unifying theory on the causes of cancer metastases has been proposed by Alexander R.A. Anderson, Ph.D., chair of Integrated Mathematical Oncology at Moffitt Cancer Center, and Jacob Scott, M.D., a Moffitt Radiation Oncology Program resident that is studying for his Ph.D. at the University of Oxford Centre for Mathematical Biology.

15 Jun 2012

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) that treats cancer patients with promising new drugs.

15 Jun 2012

Study reveals molecular link between aging and cancer

It has long been known that cancer is a disease of aging, but a molecular link between the two has remained elusive.

15 Jun 2012

AMPK enzyme promotes survival of cancer cells: Research

A molecule thought to limit cell proliferation also helps cancer cells survive during initial tumor formation and when the wayward cells spread to other organs in the body, researchers at the University of Illinois at Chicago College of Medicine have found.

15 Jun 2012

Antibody that blocks programmed cell death benefits cancer patients

A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).

14 Jun 2012

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Patients with locally advanced pancreatic cancer have a more favorable prognosis after palliative chemoradiotherapy if they have previously been treated with a gemcitabine-based therapy, say Danish researchers.

14 Jun 2012

Scientists discover one of the most important cellular mechanisms behind meningioma

Johns Hopkins researchers say they have discovered one of the most important cellular mechanisms driving the growth and progression of meningioma, the most common form of brain and spinal cord tumor. A report on the discovery, published in the journal Molecular Cancer Research, could lead the way to the discovery of better drugs to attack these crippling tumors, the scientists say.

14 Jun 2012

Advaxis announces publication of preclinical research with ADXS-PSA

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.

14 Jun 2012

Reovirus can trick the body's defenses to reach and kill cancer cells

Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumors undetected by hitching a ride on blood cells.

14 Jun 2012

Cancers often recur after treatment with single drugs that “target” tumor cells’ genetic pathways

Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.

14 Jun 2012